Trials / Completed
CompletedNCT06008652
A Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DR-0201 in Healthy Adult Volunteers
A First-in-Human Multiple Expansion Cohort Phase 1 Study Evaluating the Safety and Activity of DR-0201 as Single Ascending Dose in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- Dren Bio · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
This is a randomized, double-blind, placebo-controlled dose escalation study to evaluate the safety, tolerability, PK, PD, and immunogenicity of IV administered DR-0201 in healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DR-0201 | DR-0201 is a bi-specific antibody |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2023-11-26
- Primary completion
- 2024-07-24
- Completion
- 2024-07-24
- First posted
- 2023-08-23
- Last updated
- 2024-08-13
Locations
1 site across 1 country: Australia
Source: ClinicalTrials.gov record NCT06008652. Inclusion in this directory is not an endorsement.